Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$21.4M-1.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.44M-14.8%
Arrowhead Research logo
Arrowhead ResearchARWR
$7.77M+14.6%
Alkermes logo
AlkermesALKS
$7.58M+20.4%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$1.8M+32.2%
Viatris logo
ViatrisVTRS
$101.7M-1.5%

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's operating lease liabilities (current)?
Halozyme Therapeutics (HALO) reported operating lease liabilities (current) of $32.42M in Q1 2026.
How has Halozyme Therapeutics's operating lease liabilities (current) changed year-over-year?
Halozyme Therapeutics's operating lease liabilities (current) increased by 10.3% year-over-year, from $29.39M to $32.42M.
What is the long-term trend for Halozyme Therapeutics's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Halozyme Therapeutics's operating lease liabilities (current) has grown at a 48.0% compound annual growth rate (CAGR), from $4.87M to $34.57M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.